Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omarigliptin vs Sitagliptin in T2DM on Metformin
NCT01841697Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2013
- Primary completion
- Nov 2014
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of omarigliptin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started Jun 2013; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01841697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01841697.